Welcome to our dedicated page for 10X Genomics SEC filings (Ticker: TXG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
10x Genomics, Inc. filings document regulatory disclosures for a Nasdaq-listed life science technology company with Class A common stock. Form 8-K reports furnish quarterly and annual operating results, selected preliminary results and business updates related to single cell and spatial biology platforms, including instruments, consumables, software and product launches.
The filing record also includes definitive proxy materials covering board matters, executive compensation, equity awards and shareholder voting items, as well as Form 8-K disclosure for executive officer transitions and related compensation arrangements. These documents describe TXG's public-company governance, registered security, financial reporting events and material corporate updates.
Vanguard Portfolio Management reports beneficial ownership of 6,981,683 shares of 10X Genomics Inc. common stock, representing 5.93% of the class. The filing states Vanguard exercises dispositive power over these shares through Vanguard Portfolio Management LLC and certain affiliates.
The filing discloses 68,747 shares of sole voting power and 6,981,683 shares of sole dispositive power. The disclosure covers shares held for Vanguard funds and client accounts; affiliate holdings disaggregated from this reporting unit are excluded.
10x Genomics, Inc. is holding its 2026 annual meeting virtually on June 4, 2026 at 11:30 a.m. PDT, asking stockholders to elect three Class I directors, ratify Ernst & Young LLP as auditor for 2026, and approve an advisory “Say on Pay” vote on executive compensation.
The company uses a dual-class structure with 118,912,062 Class A shares (one vote each) and 10,078,872 Class B shares (ten votes each) entitled to vote as of April 8, 2026. The board is majority independent, has an independent chair, and operates fully independent audit, compensation, and nominating and governance committees.
For 2025, 10x Genomics reports $643 million in revenue, including $44 million from patent litigation settlements, a 69% gross margin, and $523 million in cash, cash equivalents and marketable securities. Executive pay combines salary, an annual incentive plan tied to revenue, adjusted free cash flow and strategic objectives, and performance-based equity linked to relative total shareholder return and revenue growth.
10x Genomics, Inc. Chief Executive Officer Serge Saxonov sold 5,000 shares of Class A Common Stock in an open-market transaction at a weighted average price of $24.5568 per share on April 14, 2026. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 29, 2025, indicating it was scheduled in advance.
Following the sale, Saxonov directly holds 1,167,273 shares of Class A Common Stock. He also has indirect holdings through trusts where he serves as trustee, including 27 shares in the Andromeda Trust, 213,250 shares in the Y/S Descendants' Trust, and 71,644 shares in the Y/S Pot Trust.
10x Genomics, Inc. CEO Serge Saxonov reported open‑market sales of 15,000 shares of Class A Common Stock. He sold 10,000 shares on March 23, 2026 at a weighted average price of $19.1297 per share and 5,000 shares on March 24, 2026 at a weighted average price of $19.5223 per share.
The filing states these transactions were executed under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 29, 2025. After the sales, he directly holds 1,172,273 shares of Class A Common Stock and also has significant additional indirect and Class B holdings held through various trusts where he serves as trustee, with each Class B share convertible into one Class A share.
10X Genomics Inc Schedule 13G/A amendment shows The Vanguard Group reporting zero shares beneficially owned of Common Stock after an internal realignment effective January 12, 2026. The filing states Vanguard's subsidiaries will report beneficial ownership separately in reliance on SEC Release No. 34-39538.
The filing records 0 shares beneficially owned and 0% of the class, with no sole or shared voting or dispositive power listed. The signature block is by Ashley Grim, Head of Global Fund Administration dated 03/25/2026.
10X Genomics Inc ownership filing: The Vanguard Group filed an amendment to a Schedule 13G reporting 0 shares beneficially owned of Common Stock, representing 0% of the class. The filing states Vanguard and related managed accounts have rights to dividends or sale proceeds but hold no >5% interest.
FMR LLC reports beneficial ownership of 18,543,561.62 shares of Class A common stock of 10x Genomics, Inc. as of February 27, 2026, representing 15.6% of the Class A shares. The filing notes that 892,772 shares of Class B common stock held by Fidelity-advised investment companies are included in this figure and are convertible into Class A on a 1:1 basis.
The filing also lists Abigail P. Johnson with shared reporting authorities tied to the same 18,543,561.62-share position. The schedule states: "Assuming the conversion of all outstanding shares of Class B Common Stock into Class A Common Stock, the 18,543,561 shares ... would represent 14.5153% of the outstanding Class A Common Stock."
10x Genomics, Inc. Chief Executive Officer Serge Saxonov reported planned share sales and a gift of stock. On March 2, 2026, he sold a total of 16,152 shares of Class A common stock in open-market transactions at weighted average prices of $22.6690 and $23.1781, effected under a Rule 10b5-1 trading plan adopted on November 29, 2025. On March 3, 2026, he made a bona fide gift of 2,750 shares at no consideration. After these transactions, he directly held 1,200,917 shares of Class A common stock, and also had indirect holdings of 27 shares in the Andromeda Trust, 213,250 shares in the Y/S Descendants' Trust, and 58,000 shares in the Y/S Pot Trust, for which he serves as trustee.
10x Genomics, Inc. reported that Chief Executive Officer Serge Saxonov acquired an equity award in the form of restricted stock units covering 157,895 shares of Class A Common Stock at a stated price of $0.00 per share on February 26, 2026.
Each RSU represents a right to receive one share of Class A Common Stock upon vesting. According to the terms, 1/12 of the RSUs vest on each quarterly anniversary starting from February 21, 2026, as long as he continues as a service provider on each vesting date.
The filing also lists indirect holdings of Class A Common Stock held by the Andromeda Trust, the Y/S Descendants' Trust, and the Y/S Pot Trust, for which Saxonov serves as trustee, totaling separate positions of 27, 213,250, and 58,000 shares respectively.
Hindson Benjamin J. reported acquisition or exercise transactions in this Form 4 filing.
10x Genomics, Inc. reported that director and officer Benjamin J. Hindson received a grant of 88,816 restricted stock units (RSUs) linked to its Class A Common Stock at a stated price of $0.00 per share. Each RSU represents a right to receive one share upon vesting.
According to the award terms, 1/12 of the RSUs will vest on each quarterly anniversary starting on February 21, 2026, as long as Hindson continues as a service provider through each vesting date. After this grant, his directly held Class A Common Stock, including RSUs, totals 513,595 shares.